The purpose of this study is to investigate the glycaemic control and other clinical parameters in adult patients previously treated with basal insulin (with or without OADs) and switched to IDegLira in real-world clinical practice in Colombia.
Study Type
OBSERVATIONAL
Enrollment
175
Collecting data reported in medical records of patients with T2D, who had initiated treatment with commercially available IDegLira according to the routine clinical practice and local label at the discretion of the treating physician
Novo Nordisk Investigational Site
Medellín, Antioquia, Colombia
Novo Nordisk Investigational Site
Barranquilla, Atlántico, Colombia
Novo Nordisk Investigational Site
Bogotá, Bogota DC, Colombia
Novo Nordisk Investigational Site
Montería, Departamento de Córdoba, Colombia
Change in local laboratory measured Glycated Haemoglobin A1c (HbA1c)
Percentage point
Time frame: From baseline (week 0) to end of study (week 26 plus/minus 6 weeks) after IDegLira initiation
Change in absolute body weight
Kilogram (kg)
Time frame: From baseline (week 0) to end of study (week 26 plus/minus 6 weeks) after IDegLira initiation
Comparison between the daily dose of basal insulin and IDegLira
Units/day
Time frame: From baseline (week 0) to end of study (week 26 plus/minus 6 weeks) after IDegLira initiation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Novo Nordisk Investigational Site
Cúcuta, Norte de Santander Department, Colombia
Novo Nordisk Investigational Site
Bucaramanga, Santander Department, Colombia